These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27287854)

  • 21. [Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris].
    Chams-Davatchi C; Nonahal Azar R; Daneshpazooh M; Valikhani M; Hallaji Z; Barzegari M; Firouz AR; Zakeri M
    Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):23-5. PubMed ID: 11937925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
    Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
    Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pemphigus vulgaris: an evidence-based treatment update.
    Zhao CY; Murrell DF
    Drugs; 2015 Feb; 75(3):271-84. PubMed ID: 25655250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects.
    Svecova D
    Australas J Dermatol; 2016 May; 57(2):141-4. PubMed ID: 26581165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus.
    Doukaki S; Pistone G; Aricò M; Bongiorno MR
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):237-44. PubMed ID: 21192770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of pemphigus.
    Tsuruta D; Ishii N; Hashimoto T
    Immunotherapy; 2012 Jul; 4(7):735-45. PubMed ID: 22853759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infective endocarditis in two patients with pemphigus vulgaris under multiagent immunosuppressive drug therapy: A rare entity to remember in the differential diagnosis of fever of unknown origin.
    Küçükoğlu R; Kılıç S; Sun GP
    Dermatol Ther; 2019 May; 32(3):e12860. PubMed ID: 30758911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis.
    Atzmony L; Hodak E; Gdalevich M; Rosenbaum O; Mimouni D
    Am J Clin Dermatol; 2014 Dec; 15(6):503-15. PubMed ID: 25403548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of pemphigus disease in pregnancy.
    Tavakolpour S; Mirsafaei HS; Delshad S
    Am J Reprod Immunol; 2017 Jan; 77(1):. PubMed ID: 27862562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pemphigus vulgaris: a case-based update.
    Ben Lagha N; Poulesquen V; Roujeau JC; Alantar A; Maman L
    J Can Dent Assoc; 2005 Oct; 71(9):667-72. PubMed ID: 16271165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Think globally, act locally: expert opinions from Asia on the diagnosis and treatment of pemphigus vulgaris.
    Samadi Z; Gorouhi F; Davari P; Firooz A
    Indian J Med Sci; 2007 Mar; 61(3):144-51. PubMed ID: 17337815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N; Patel NS; Cohen GF
    J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for pemphigus foliaceus.
    Fernando SL; Broadfoot AJ
    G Ital Dermatol Venereol; 2009 Aug; 144(4):363-77. PubMed ID: 19755942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
    Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
    Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemphigus Vulgaris Aggravated: Rifampicin Found at the Scene of the Crime.
    Hu L; Sun Y; Gao Z; Wang P
    Cutis; 2022 May; 109(5):E19-E21. PubMed ID: 35856757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
    De Simone C; Caldarola G; Perino F; Venier A; Guerriero G
    Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.